Marcus A Mall Selected Research

Cystic Fibrosis (Mucoviscidosis)

12/2022	Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 Through 11 Years of Age with Cystic Fibrosis Heterozygous for F508del and a Minimal Function Mutation: A Phase 3b, Randomized, Placebo-controlled Study.
11/2022	Magnetic resonance imaging detects improvements of pulmonary and paranasal sinus abnormalities in response to elexacaftor/tezacaftor/ivacaftor therapy in adults with cystic fibrosis.
11/2022	Macrophage PD-1 associates with neutrophilia and reduced bacterial killing in early cystic fibrosis airway disease.
1/2022	Effects of Elexacaftor/Tezacaftor/Ivacaftor Therapy on Lung Clearance Index and Magnetic Resonance Imaging in Patients with Cystic Fibrosis and One or Two F508del Alleles.
1/2022	Final results of the southwest German pilot study on cystic fibrosis newborn screening - Evaluation of an IRT/PAP protocol with IRT-dependent safety net.
1/2022	Effects of Elexacaftor/Tezacaftor/Ivacaftor Therapy on CFTR Function in Patients with Cystic Fibrosis and One or Two F508del Alleles.
1/2022	A PI3Kγ mimetic peptide triggers CFTR gating, bronchodilation, and reduced inflammation in obstructive airway diseases.
1/2022	Efficacy and safety of inhaled ENaC inhibitor BI 1265162 in patients with cystic fibrosis: BALANCE-CF 1, a randomised, phase II study.
1/2022	Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week, multicentre, randomised, double-blind, active-controlled, phase 3b trial.
12/2021	Triple Therapy for Cystic Fibrosis Phe508del-Gating and -Residual Function Genotypes. Reply.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Marcus A Mall Research Topics

Disease

76	Cystic Fibrosis (Mucoviscidosis) 12/2022 - 02/2009
49	Lung Diseases (Lung Disease) 01/2022 - 12/2008
32	Inflammation (Inflammations) 01/2022 - 03/2008
12	Chronic Obstructive Pulmonary Disease (COPD) 05/2021 - 04/2008
11	Infections 11/2022 - 01/2012
9	COVID-19 01/2022 - 08/2020
9	Obstructive Lung Diseases (Obstructive Lung Disease) 01/2022 - 01/2016
9	Asthma (Bronchial Asthma) 01/2022 - 01/2011
7	Pneumonia (Pneumonitis) 03/2021 - 01/2012
7	Metaplasia 07/2017 - 03/2008
5	Necrosis 01/2020 - 12/2008
5	Dehydration (Water Stress) 01/2016 - 04/2009
4	Fibrosis (Cirrhosis) 01/2022 - 10/2017
4	Bronchiectasis 05/2021 - 01/2018
4	Bacterial Infections (Bacterial Infection) 11/2018 - 05/2014
4	Emphysema 04/2015 - 05/2014
3	Chronic Disease (Chronic Diseases) 01/2020 - 12/2008
3	Eosinophilia 01/2020 - 04/2009
3	Inborn Genetic Diseases (Disease, Hereditary) 01/2018 - 02/2009
2	Neoplasms (Cancer) 11/2022 - 01/2017
2	Persistent Infection 11/2022 - 01/2020
2	Respiratory Tract Diseases (Respiratory Tract Disease) 01/2022 - 01/2021
2	Idiopathic Pulmonary Fibrosis 06/2021 - 10/2017
2	Disease Progression 05/2021 - 08/2020
2	Airway Remodeling 01/2015 - 12/2008
1	Sepsis (Septicemia) 11/2022
1	Psychotic Disorders (Schizoaffective Disorder) 01/2022
1	Meconium Ileus 01/2022
1	Interstitial Lung Diseases (Interstitial Lung Disease) 01/2022
1	Lung Neoplasms (Lung Cancer) 01/2022
1	Obsessive-Compulsive Disorder (Disorder, Obsessive-Compulsive) 01/2022

Drug/Important Bio-Agent (IBA)

22	Cystic Fibrosis Transmembrane Conductance Regulator (Protein, CFTR)IBA 01/2022 - 02/2009
11	elexacaftorIBA 12/2022 - 10/2018
10	ChloridesIBA 12/2022 - 10/2012
10	ivacaftor drug combination tezacaftorIBA 12/2022 - 10/2018
9	Proteins (Proteins, Gene)FDA Link 11/2022 - 04/2009
9	MucinsIBA 06/2021 - 04/2008
8	Biomarkers (Surrogate Marker)IBA 05/2021 - 01/2011
7	ivacaftorIBA 01/2022 - 11/2015
7	Peptide Hydrolases (Proteases)FDA Link 05/2021 - 02/2014
6	Leukocyte Elastase (Neutrophil Elastase)IBA 01/2022 - 05/2014
6	CytokinesIBA 12/2021 - 04/2008
5	Interleukin-1 (Interleukin 1)IBA 01/2022 - 01/2017
5	Epithelial Sodium ChannelsIBA 01/2022 - 09/2015
5	Interleukin-8 (Interleukin 8)IBA 09/2021 - 11/2015
5	lumacaftorIBA 03/2021 - 01/2018
5	Chloride Channels (Chloride Channel)IBA 01/2018 - 07/2012
4	InterleukinsIBA 01/2022 - 11/2015
4	Immunoglobulin G (IgG)IBA 10/2021 - 01/2021
4	AntibodiesIBA 10/2021 - 11/2012
4	Interleukin-1 Receptors (Interleukin 1 Receptor)IBA 01/2020 - 04/2015
4	Anti-Bacterial Agents (Antibiotics)IBA 01/2020 - 03/2016
4	SmokeIBA 11/2018 - 11/2014
4	Interleukin-13IBA 07/2017 - 04/2008
4	Amiloride (Midamor)FDA LinkGeneric 07/2017 - 12/2008
4	ChitinasesIBA 12/2015 - 04/2008
3	Ion Channels (Ion Channel)IBA 01/2022 - 09/2015
3	Chemotactic FactorsIBA 01/2022 - 09/2013
3	Messenger RNA (mRNA)IBA 10/2021 - 11/2015
3	cathepsin SIBA 01/2021 - 07/2014
3	DNA (Deoxyribonucleic Acid)IBA 11/2020 - 10/2010
3	AllergensIBA 01/2020 - 01/2017
3	Pancreatic Elastase (Elastase)IBA 01/2020 - 01/2018
3	Interleukin 1 Receptor Antagonist Protein (Anakinra)FDA Link 01/2020 - 04/2015
3	AnionsIBA 04/2019 - 11/2015
3	IronIBA 06/2017 - 01/2012
3	LipopolysaccharidesIBA 11/2015 - 01/2012
2	EnzymesIBA 11/2022 - 01/2020
2	tezacaftorIBA 01/2022 - 11/2019
2	GlucocorticoidsIBA 01/2022 - 04/2009
2	Peptides (Polypeptides)IBA 01/2022 - 10/2021
2	Antiviral Agents (Antivirals)IBA 12/2021 - 01/2020
2	Protease Inhibitors (Protease Inhibitor)IBA 05/2021 - 01/2016
2	Vitamin A (Retinol)FDA LinkGeneric 03/2021 - 01/2015
2	VitaminsIBA 03/2021 - 01/2015
2	LipidsIBA 03/2021 - 01/2015
2	Serine Proteases (Serine Protease)IBA 01/2021 - 03/2019
2	NitrogenIBA 10/2020 - 01/2020
2	Pharmaceutical PreparationsIBA 01/2020 - 11/2015
2	Matrix Metalloproteinase 12IBA 12/2016 - 11/2014
2	TrypsinogenIBA 11/2016 - 10/2010
2	Pancreatitis-Associated ProteinsIBA 11/2016 - 10/2010
2	MicroRNAs (MicroRNA)IBA 12/2015 - 11/2015
2	GoldIBA 07/2014 - 05/2013
2	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 04/2009 - 04/2008
1	Phosphoric Diester Hydrolases (Phosphodiesterases)IBA 01/2022
1	68Ga-FAPIIBA 01/2022
1	Cyclic AMP-Dependent Protein Kinases (cAMP-Dependent Protein Kinase)IBA 01/2022
1	Adenosine (Adenocard)FDA LinkGeneric 01/2022
1	Interleukin-33IBA 01/2022
1	Complement System Proteins (Complement)IBA 01/2022
1	RNA (Ribonucleic Acid)IBA 12/2021
1	Transcription Factors (Transcription Factor)IBA 11/2021
1	BNT162 VaccineIBA 10/2021
1	Interleukin-6 (Interleukin 6)IBA 09/2021
1	Surface-Active Agents (Surfactants)IBA 06/2021

Therapy/Procedure

36	Therapeutics 11/2022 - 04/2008
3	Fluid Therapy (Oral Rehydration Therapy) 07/2014 - 09/2013
1	PPA protocol 01/2022
1	Medical Day Care (Partial Hospitalization) 11/2021